Roivant Sciences(ROIV) - 2026 Q3 - Quarterly Report

Financial Performance - Total revenue for the three months ended December 31, 2025, was $1,999,000, a decrease from $9,018,000 in the same period of 2024[29] - The net loss attributable to Roivant Sciences Ltd. for the three months ended December 31, 2025, was $265,891,000, compared to a net income of $169,381,000 in the same period of 2024[29] - The company reported a net loss of $1.13 billion for the quarter, compared to a net loss of $5.25 billion in the previous quarter, indicating a significant improvement[36] - For the nine months ended December 31, 2025, the company reported a net loss of $753.7 million, compared to a net loss of $104.4 million for the same period in 2024[40] - The company reported a net loss of $265,891 for the period, compared to a loss of $47,810 in the previous period, indicating a significant increase in losses[37] Operating Expenses - Operating expenses for the three months ended December 31, 2025, totaled $341,152,000, compared to $283,399,000 for the same period in 2024, reflecting an increase of 20.4%[29] - Research and development expenses for the three months ended December 31, 2025, were $165,380,000, compared to $141,595,000 for the same period in 2024, an increase of 16.8%[29] - General and administrative expenses for the three months ended December 31, 2025, were $175,072,000, compared to $141,545,000 for the same period in 2024, an increase of 23.7%[29] - The company incurred share-based compensation of $269.0 million for the nine months ended December 31, 2025, up from $205.5 million in 2024, indicating a 30.2% increase[40] - Personnel-related expenses increased by $21.2 million for the nine months ended December 31, 2025, primarily due to higher headcount to support additional clinical studies[180] Cash and Assets - Cash and cash equivalents decreased to $1,478,270,000 as of December 31, 2025, from $2,715,411,000 as of March 31, 2025[27] - Total assets as of December 31, 2025, were $5,225,368,000, down from $5,436,940,000 as of March 31, 2025[27] - The company had cash, cash equivalents, and marketable securities totaling approximately $4.5 billion as of December 31, 2025[196] - As of December 31, 2025, total cash, cash equivalents, and marketable securities amounted to $4,529.978 million, a decrease from $4,886.891 million as of March 31, 2025[79] Shareholder Equity - Shareholders' equity attributable to Roivant Sciences Ltd. decreased to $4,269,255,000 as of December 31, 2025, from $4,687,605,000 as of March 31, 2025[27] - Total shareholders' equity as of June 30, 2025, is $4,815,906, a decrease from $5,187,198 on March 31, 2025[35] - The company repurchased 20,269,450 common shares, leading to a reduction of $208,293 in shareholders' equity[35] - The company completed a share repurchase program, repurchasing 71,251,083 shares from Sumitomo for approximately $648.4 million at a price of $9.10 per share[99] Investments and Acquisitions - The company sold its entire equity interest in its majority-owned subsidiary Telavant Holdings, Inc. for approximately $5.2 billion in cash in December 2023[46] - The Company completed the acquisition of Dermavant Sciences Ltd. by Organon in October 2024, classifying the results as discontinued operations[54] - The company has successfully completed a strategic acquisition, enhancing its capabilities in the technology sector[36] Future Outlook - Future guidance suggests a revenue increase of 15% for the next quarter, driven by anticipated demand for new products[36] - The company is investing in new technology development, with a budget allocation of $160 million for R&D in the next fiscal year[36] - The company is focusing on expanding its market presence and has plans for new product launches in the upcoming quarters[36] Financial Risks and Controls - The company does not currently face significant foreign currency exchange rate risk, as most expenses are denominated in U.S. dollars[218] - The company maintains effective disclosure controls and procedures as of December 31, 2025, ensuring timely and accurate reporting[223] - There were no significant changes in critical accounting policies or estimates from the previous fiscal year[215] Miscellaneous - The company appointed Frank Torti as President and Vant Chair, with a compensation package including PSUs valued at $85.1 million and RSUs valued at $20.9 million[104] - The company has a remaining minimum obligation for the contract manufacturing of batoclimab drug substance of approximately $39.1 million as of December 31, 2025[198] - The board of directors authorized a common share repurchase program allowing for repurchases of up to $500 million, with no purchases made as of December 31, 2025[201]